Ernexa Therapeutics Inc

Research Ernexa Therapeutics Inc (ERNA) on Bullrun: market cap USD 8.20M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerERNA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 8.20M
• Financial periodFY2025
• Net income-USD 14.08M
• Free cash flow-USD 7.05M

Valuation Snapshot

latest market cap is USD 8.20M.

About Ernexa Therapeutics Inc

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited.

Frequently asked questions

What is Ernexa Therapeutics Inc's market cap?

Ernexa Therapeutics Inc's market capitalization is USD 8.20M.

What does Ernexa Therapeutics Inc do?

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.